142 related articles for article (PubMed ID: 8695248)
21. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
Perez EA; Hesketh P; Sandbach J; Reeves J; Chawla S; Markman M; Hainsworth J; Bushnell W; Friedman C
J Clin Oncol; 1998 Feb; 16(2):754-60. PubMed ID: 9469367
[TBL] [Abstract][Full Text] [Related]
22. Randomized, double-blind comparison of granisetron versus granisetron plus prednisolone as antiemetic prophylaxis during multiple-day cisplatin-based chemotherapy.
Handberg J; Wessel V; Larsen L; Herrstedt J; Hansen HH
Support Care Cancer; 1998 Jan; 6(1):63-7. PubMed ID: 9458539
[TBL] [Abstract][Full Text] [Related]
23. A randomised, double-blind, parallel-group study to compare the efficacy and safety of ondansetron (GR38032F) plus dexamethasone with metoclopramide plus dexamethasone in the prophylaxis of nausea and emesis induced by carboplatin chemotherapy.
du Bois A; McKenna CJ; Andersson H; Lahousen M; Kitchener H; Pinter T; Capstick V; Wilkinson JR
Oncology; 1997; 54(1):7-14. PubMed ID: 8978585
[TBL] [Abstract][Full Text] [Related]
24. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
25. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
Audhuy B; Cappelaere P; Martin M; Cervantes A; Fabbro M; Rivière A; Khayat D; Bleiberg H; Faraldi M; Claverie N; Aranda E; Auclerc G; Audhuy B; Benhammouda A; Bleiberg H; Cals L; Cappelaere P; Cattan A; Cervantes A; Chevallier B; Conroy T; Cupissol D; De Grève J; Diaz-Rubio E; Seitz JF
Eur J Cancer; 1996 May; 32A(5):807-13. PubMed ID: 9081358
[TBL] [Abstract][Full Text] [Related]
26. Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy.
Fox SM; Einhorn LH; Cox E; Powell N; Abdy A
J Clin Oncol; 1993 Dec; 11(12):2391-5. PubMed ID: 8246028
[TBL] [Abstract][Full Text] [Related]
27. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study.
Seol YM; Kim HJ; Choi YJ; Lee EM; Kim YS; Oh SY; Koh SJ; Baek JH; Lee WS; Joo YD; Lee HG; Yun EY; Chung JS
Support Care Cancer; 2016 Feb; 24(2):945-952. PubMed ID: 26265119
[TBL] [Abstract][Full Text] [Related]
28. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
Massidda B; Ionta MT
J Chemother; 1996 Jun; 8(3):237-42. PubMed ID: 8808724
[TBL] [Abstract][Full Text] [Related]
29. Comparison of granisetron, ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin.
Oge A; Alkiş N; Oge O; Kartum A
J Chemother; 2000 Feb; 12(1):105-8. PubMed ID: 10768522
[TBL] [Abstract][Full Text] [Related]
30. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.
Cocquyt V; Van Belle S; Reinhardt RR; Decramer ML; O'Brien M; Schellens JH; Borms M; Verbeke L; Van Aelst F; De Smet M; Carides AD; Eldridge K; Gertz BJ
Eur J Cancer; 2001 May; 37(7):835-42. PubMed ID: 11313170
[TBL] [Abstract][Full Text] [Related]
31. A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation.
Armbruster SD; Fellman BM; Jhingran A; Eifel PJ; Klopp AH; Coleman RL; Ramondetta LM; Frumovitz M
Support Care Cancer; 2021 Jan; 29(1):213-222. PubMed ID: 32338316
[TBL] [Abstract][Full Text] [Related]
32. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis.
Perez EA
J Clin Oncol; 1995 Apr; 13(4):1036-43. PubMed ID: 7707101
[TBL] [Abstract][Full Text] [Related]
33. [Anti-emetic effects of ondansetron hydrochloride throughout courses of cytotoxic chemotherapy].
Nishida T; Yakushiji M; Ohizumi K; Noda S; Rikimaru T; Matsuoka K
Gan To Kagaku Ryoho; 2002 Jan; 29(1):81-7. PubMed ID: 11816483
[TBL] [Abstract][Full Text] [Related]
34. Comparison of two different doses of ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced emesis.
Pectasides D; Mylonakis A; Varthalitis J; Kostopoulou M; Constantinou A; Papazachariou K; Antoniou F; Dimitriadis M; Athanassiou A
Oncology; 1997; 54(1):1-6. PubMed ID: 8978584
[TBL] [Abstract][Full Text] [Related]
35. [Anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting--a randomized clinical trial].
Zeng WY
Zhonghua Zhong Liu Za Zhi; 1992 Jul; 14(4):273-5. PubMed ID: 1396075
[TBL] [Abstract][Full Text] [Related]
36. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W
J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of ondansentron treatment for acute emesis with different dosing schedules 8 vs 32 mg. A randomized study.
Tsavaris N; Kosmas CH; Vadiaka M; Kontos A; Katsorida M; Dimitrakopoulos A; Zerai A; Koufos CH
J Exp Clin Cancer Res; 2001 Mar; 20(1):29-34. PubMed ID: 11370826
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis.
Perez EA; Navari RM; Kaplan HG; Gralla RJ; Grunberg SM; Palmer RH; Fitts D
Support Care Cancer; 1997 Jan; 5(1):31-7. PubMed ID: 9010987
[TBL] [Abstract][Full Text] [Related]
39. Oral ondansetron in the prevention of chemotherapy-induced emesis in breast cancer patients. French Ondansetron Study Group.
Clavel M; Bonneterre J; d'Allens H; Paillarse JM
Eur J Cancer; 1995; 31A(1):15-9. PubMed ID: 7695971
[TBL] [Abstract][Full Text] [Related]
40. Patients' self-reported functional status after granisetron or ondansetron therapy to prevent chemotherapy-induced nausea and vomiting at six cancer centers.
Farley PA; Dempsey CL; Shillington AA; Kulis-Robitaille C; Colgan K; Bernstein G
Am J Health Syst Pharm; 1997 Nov; 54(21):2478-82. PubMed ID: 9359954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]